231 related articles for article (PubMed ID: 30411455)
1. Primavera: A new therapeutical approach to vulvo-vaginal atrophy.
Amori P; Di Nardo V; Vitiello G; Franca K; Hercogova J; Wollina U; Daaboul F; Tchernev G; Lotti T
Dermatol Ther; 2018 Nov; 31(6):e12678. PubMed ID: 30411455
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
3. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Villa P; Tagliaferri V; Amar ID; Cipolla C; Ingravalle F; Scambia G; Ricciardi W; Lanzone A
Gynecol Endocrinol; 2020 Jun; 36(6):535-539. PubMed ID: 31847628
[TBL] [Abstract][Full Text] [Related]
4. Structure of Epithelial and Stromal Compartments of Vulvar and Vaginal Tissue From Women With Vulvo-Vaginal Atrophy Taking Ospemifene.
Alvisi S; Baldassarre M; Gava G; Mancini I; Gagliardi M; Seracchioli R; Meriggiola MC
J Sex Med; 2018 Dec; 15(12):1776-1784. PubMed ID: 30446472
[TBL] [Abstract][Full Text] [Related]
5. Symptoms, attitudes and treatment perceptions of vulvo-vaginal atrophy in UK postmenopausal women: Results from the REVIVE-EU study.
Domoney C; Short H; Particco M; Panay N
Post Reprod Health; 2020 Jun; 26(2):101-109. PubMed ID: 32627698
[TBL] [Abstract][Full Text] [Related]
6. Non-hormonal treatment of vulvo-vaginal atrophy-related symptoms in post-menopausal women.
Tersigni C; Di Simone N; Tempestilli E; Cianfrini F; Russo R; Moruzzi MC; Amar ID; Fiorelli A; Scambia G; Villa P
J Obstet Gynaecol; 2015; 35(8):835-8. PubMed ID: 25968636
[TBL] [Abstract][Full Text] [Related]
7. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
8. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
Vicariotto F; DE Seta F; Faoro V; Raichi M
Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
[TBL] [Abstract][Full Text] [Related]
9. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.
Lev-Sagie A
Clin Obstet Gynecol; 2015 Sep; 58(3):476-91. PubMed ID: 26125962
[TBL] [Abstract][Full Text] [Related]
10. Use of Growth Factors for Vulvo/Vaginal Bio-Stimulation.
Isaza PG
Surg Technol Int; 2019 May; 34():269-273. PubMed ID: 30388724
[TBL] [Abstract][Full Text] [Related]
11. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
12. An overview of chronic vaginal atrophy and options for symptom management.
Woods NF
Nurs Womens Health; 2012 Dec; 16(6):482-93; quiz 494. PubMed ID: 23253575
[TBL] [Abstract][Full Text] [Related]
13. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
Vicariotto F; Raichi M
Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
[TBL] [Abstract][Full Text] [Related]
14. Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder.
Caruso S; Mauro D; Cariola M; Fava V; Rapisarda AMC; Cianci A
Gynecol Endocrinol; 2018 Feb; 34(2):110-114. PubMed ID: 28749253
[TBL] [Abstract][Full Text] [Related]
15. Vaginal Health During Breast Cancer Treatment.
Falk SJ; Bober S
Curr Oncol Rep; 2016 May; 18(5):32. PubMed ID: 27074843
[TBL] [Abstract][Full Text] [Related]
16. Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women.
Samuels JB; Garcia MA
Aesthet Surg J; 2019 Jan; 39(1):83-93. PubMed ID: 29726916
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators and vulvovaginal atrophy: can we improve the lives of our patients with new therapeutic options?
Shulman LP
Menopause; 2010; 17(3):452-3. PubMed ID: 20464782
[No Abstract] [Full Text] [Related]
18. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
19. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy.
Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
Maturitas; 2019 Mar; 121():86-92. PubMed ID: 30509753
[TBL] [Abstract][Full Text] [Related]
20. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
Nappi RE; Seracchioli R; Salvatore S; Cagnacci A; Di Paolantonio T; Busacca M;
Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
